FarmaKology Newsletter - Issue #81
Would you like to submit an article, some interesting news, or get your startup featured? Send whatever you have to?“[email protected]”, and happy to have you featured on our newsletter?(+12K Subscribers )!
Today's Company
Mogrify??has developed a proprietary suite of platform technologies that utilize a systematic big-data approach to direct cellular reprogramming (Rackham et al., Nature Genetics, 2016) and the maintenance of cell identity (Kamaraj et al., Cell Systems 2020). The platforms, developed over a 12-year period via a multi-national research collaboration, deploy next-generation sequencing, gene regulatory and epigenetic network data to enable the prediction of the transcription factors and culture medium conditions required to produce any target cell type from any source cell type. The platform can be used to enhance existing stem-cell forward reprogramming methods or can bypass development pathways altogether, affecting a direct transdifferentiating between a mature cell type to another mature cell type. Mogrify is applying its proprietary and award-winning platforms to engineer an evergreen and scalable source of cell types that exhibit efficacy and safety profiles necessary to transform the development of ex vivo cell therapies and pioneer a new class of in vivo reprogramming therapies for indications of high unmet clinical need in hematological, immunological, ophthalmological and other disease areas.
News
?The?U.S.?Food and Drug Administration?(FDA)?has approved an expanded label for?Eli Lilly and Company’s?rapid-acting insulin, Lyumjev??(insulin lispro-aabc injection) 100 units/mL indicated to improve glycemic control in adults with type 1 and type 2 diabetes, to include administration via continuous subcutaneous insulin infusion (CSII) with an insulin pump.
Eisai Co., Ltd.?announced today that it has launched the anticancer agent EZH2 inhibitor “Tazverik??Tablets 200 mg” (tazemetostat hydrobromide), in Japan with the indication of relapsed or refractory?EZH2?gene mutation-positive follicular lymphoma (only when standard treatment is not applicable).
BioAgilytix Labs, LLC?, a leading global contract research laboratory focused on supporting its pharmaceutical and biotech partners in all stages of large molecule drug development, announced today that it signed a definitive agreement to purchase?360biolabs?, the most comprehensive contract research organization in Australia.?
Exelixis, Inc.?and?Invenra, Inc.?today announced that they have expanded their discovery and licensing collaboration to include an additional 20 oncology targets. The augmented partnership builds on the two companies’ ongoing collaboration and license agreement to discover and develop mono-specific and multi-specific antibodies for incorporation into novel biologics to treat cancer, which was originally announced in?May 2018?and expanded in?October 2019.
Research & Study
领英推荐
Podcast
Job Opportunities
Upcoming Webinar
Video